{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T05:26:16Z","timestamp":1790141176300,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018M3A9H4089602"],"award-info":[{"award-number":["NRF-2018M3A9H4089602"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["KK1603-C00"],"award-info":[{"award-number":["KK1603-C00"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003704","name":"Korea Research Institute of Chemical Technology","doi-asserted-by":"publisher","award":["KK2032-10"],"award-info":[{"award-number":["KK2032-10"]}],"id":[{"id":"10.13039\/501100003704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bmc.2020.115679","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T22:08:24Z","timestamp":1596146904000},"page":"115679","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection"],"prefix":"10.1016","volume":"28","author":[{"given":"Xiaoli","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Seul","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daulat B.","family":"Khadka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meehyein","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won-Jea","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2020.115679_b0005","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","article-title":"Global epidemiology and burden of HCV infection and HCV-related disease","volume":"14","author":"Thrift","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bmc.2020.115679_b0010","doi-asserted-by":"crossref","first-page":"5646","DOI":"10.19082\/5646","article-title":"Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection","volume":"9","author":"Moosavy","year":"2017","journal-title":"Electron Physician"},{"key":"10.1016\/j.bmc.2020.115679_b0015","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/cid\/cis1202","article-title":"Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting","volume":"56","author":"Lloyd","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bmc.2020.115679_b0020","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030\u2013What will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.bmc.2020.115679_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2013.08.019","article-title":"Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents","volume":"68","author":"Conteduca","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.bmc.2020.115679_b0030","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/2050640619840149","article-title":"Hepatitis C virus therapy in advanced liver disease: Outcomes and challenges","volume":"7","author":"Ekpanyapong","year":"2019","journal-title":"Ueg J"},{"key":"10.1016\/j.bmc.2020.115679_b0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.20517\/2394-5079.2018.25","article-title":"Molecular targeting of antiviral drugs used against hepatitis C virus infection","volume":"4","author":"Irshad","year":"2018","journal-title":"Hepatoma Res"},{"key":"10.1016\/j.bmc.2020.115679_b0040","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"European Association for The Study of The Liver","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2020.115679_b0045","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2020.115679_b0050","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1055\/s-0031-1297928","article-title":"The era of direct-acting antivirals has begun: the beginning of the end for HCV?","volume":"31","author":"Vachon","year":"2011","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.bmc.2020.115679_b0055","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","article-title":"Response-guided telaprevir combination treatment for hepatitis C virus infection","volume":"365","author":"Sherman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2020.115679_b0060","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2020.115679_b0065","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0168-8278(11)60063-9","article-title":"61 once daily PSI-7977 plus pegIFN\/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with HCV GT2\/GT3","volume":"54","author":"Lalezari","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2020.115679_b0070","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, an NSSA replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"Nettles","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2020.115679_b0075","doi-asserted-by":"crossref","first-page":"6716","DOI":"10.3390\/v7122968","article-title":"Mechanisms of hepatitis C viral resistance to direct acting antivirals","volume":"7","author":"Ahmed","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2020.115679_b0080","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bmc.2020.115679_b0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5604\/01.3001.0009.8591","article-title":"Curing chronic hepatitis C: a cost comparison of the combination simeprevir plus sofosbuvir vs. protease-inhibitor-based triple therapy","volume":"16","author":"Langness","year":"2017","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.bmc.2020.115679_b0090","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/hepr.12905","article-title":"Spontaneous remission of hepatitis B virus reactivation during direct-acting antiviral agent-based therapy for chronic hepatitis C","volume":"47","author":"Sato","year":"2017","journal-title":"Hepatol Res."},{"key":"10.1016\/j.bmc.2020.115679_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/29dffb2a-5d37-4196-b166-b0b15bc2f3fd","article-title":"Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics","volume":"5","author":"Kaul","year":"2009","journal-title":"Plos Pathog"},{"key":"10.1016\/j.bmc.2020.115679_b0100","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1128\/JVI.02614-07","article-title":"Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro","volume":"82","author":"Yang","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.bmc.2020.115679_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013687","article-title":"DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A","volume":"5","author":"Coelmont","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bmc.2020.115679_b0110","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jhep.2010.01.041","article-title":"HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A\u2013cyclophilin A interaction to cyclophilin inhibitors","volume":"53","author":"Chatterji","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.bmc.2020.115679_b0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/DDDT.S30946","article-title":"Profile of alisporivir and its potential in the treatment of hepatitis C","volume":"7","author":"Gallay","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.bmc.2020.115679_b0120","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/AAC.00919-12","article-title":"Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir","volume":"56","author":"Garcia-Rivera","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2020.115679_b0125","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1128\/AAC.01627-10","article-title":"Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family","volume":"55","author":"Gregory","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2020.115679_b0130","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1128\/AAC.00693-12","article-title":"The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes","volume":"56","author":"Hopkins","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.bmc.2020.115679_b0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-065X.2008.00756.x","article-title":"Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation","volume":"228","author":"Liu","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bmc.2020.115679_b0140","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12026-011-8263-5","article-title":"Cyclophilin inhibitors: a novel class of promising host-targeting anti-HCV agents","volume":"52","author":"Gallay","year":"2012","journal-title":"Immunol Res"},{"key":"10.1016\/j.bmc.2020.115679_b0145","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1128\/AAC.00016-14","article-title":"The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance","volume":"58","author":"Chatterji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2020.115679_b0150","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1349-7006.2009.01263.x","article-title":"Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor","volume":"100","author":"Goto","year":"2009","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmc.2020.115679_b0155","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1128\/AAC.01236-09","article-title":"Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors","volume":"54","author":"Puyang","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2020.115679_b0160","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1039\/C1MD00227A","article-title":"Sangamides, a new class of cyclophilin-inhibiting host-targeted antivirals for treatment of HCV infection","volume":"3","author":"Moss","year":"2012","journal-title":"MedChemComm"},{"key":"10.1016\/j.bmc.2020.115679_b0165","doi-asserted-by":"crossref","first-page":"9546","DOI":"10.1021\/acs.jmedchem.5b01064","article-title":"Structure-based discovery of novel cyclophilin A inhibitors for the treatment of hepatitis C virus infections","volume":"58","author":"Yang","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2020.115679_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.112031","article-title":"Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment","volume":"188","author":"Han","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2020.115679_b0175","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","article-title":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome","volume":"11","author":"Wakita","year":"2005","journal-title":"Nat Med"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089620305095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089620305095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:49:34Z","timestamp":1778791774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089620305095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":35,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0968089620305095"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2020.115679","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2020.115679","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115679"}}